A. Oltra

ESHAP is an active regimen for relapsing Hodgkin's disease

Jorge Aparicio, Abraham Segura, S. Garcerá et al. · Annals of Oncology · 1999 · 125 citations · Full text

Esophagus, Immunology, Clinical Trials +3

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 111 citations · Full text

Metastatic Breast Cancer, Breast Oncology, Medicine +7

Pretreatment prognostic factors for survival in small-cell lung cancer: A new prognostic index and validation of three known prognostic indices on 341 patients

I. Maestu, María A. Pastor, José Gómez‐Codina et al. · Annals of Oncology · 1997 · 85 citations

Prognostic Evaluation, Prognostic Biomarkers, Medicine +10

Epirubicin–cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study

Cesar Pico, Miguel Martín, Carlos Jara et al. · Annals of Oncology · 2003 · 84 citations · Full text

Cost-Benefit Analysis of a Follow-up Program in Patients with Breast Cancer: A Randomized Prospective Study

A. Oltra, Ana Santaballa, B. Munárriz et al. · The Breast Journal · 2007 · 37 citations